Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma

Inclusion Criteria:

- patients with confirmed multiple myeloma

- eligible for treatment with high dose melphalan based regimen and autologous
peripheral stem cell transplant

Exclusion Criteria:

- Pregnant or lactating woman, as evaluated by serum testing within 24 hours of
administration of the first vaccine

- HIV infection confirmed by NAT, as evaluated during pre transplant testing

- Common variable immunodeficiency or other inherited systemic immunodeficiency
syndrome

- Active CNS malignancy

- Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or
cervical carcinoma after curative resection, not requiring chemotherapy.

- History of severe allergy (e.g., anaphylaxis) to any component of PCV7, PCV13, or any
diphtheria-toxoid containing vaccine.

- Inclusion on a separate trial in which patients may be randomized or otherwise
started on maintenance chemotherapies within the first 3 months of autologous
transplantation

- Patients with significant psychiatric illness likely to affect compliance, as
determined by the treating physician

- Active or uncontrolled infection

- DLCO <50 %

- LVEF <40%

- Bilirubin >2